Dasatinib Pharmacokinetics and Exposure-Response (E-R): Relationship to Safety and Efficacy in Patients (pts) with Chronic Myeloid Leukemia (Cml)

X. Wang,A. Hochhaus,H. M. Kantarjian,S. Agrawal,A. Roy,M. Pfister,T. Chen,E. Bleickardt,C. Nicaise,N. Shah
DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.3590
IF: 45.3
2008-01-01
Journal of Clinical Oncology
Abstract:3590 Background: Dasatinib is 325-fold more potent than imatinib and 16-fold more potent than nilotinib against BCR-ABL in vitro. In the randomized, dose optimization Study CA180–034 of pts with chronic phase CML, the 100 mg once daily dose was associated with similar efficacy but less frequent pleural effusion (pl eff), cytopenia, dose reduction, and interruption than the other three dosing schedules. Methods: The clinical study design has been previously described. Here we present population pharmacokinetic (PPK) and E-R analyses. Exposure measures examined included: mean steady-state (ss) concentration (Cavg), ss trough concentration (Cmin), and ss peak concentration (Cmax). E-R was characterized using a Cox proportional-hazards model. Covariates examined included: age, gender, body weight (PPK only), and history of cardiac disease (E-R only). Results: Of the 670 pts randomized, samples from 567 were evaluated for PK. Of these, 94 had a pl eff, 271 required dose reduction and 376 dose interruption. PPK analysis showed that exposure to dasatinib did not depend upon age, gender, or body weight, but was highly dependent on the dosing schedule. E-R analysis showed that the risk of pl eff was greater with increasing Cmin (2.33-fold for each doubling of Cmin, p<0.001) and increasing age (1.93-fold for each decade of life, p<0.001). Cmax and Cavg were not statistically significant predictors of pl eff. Cmin was also correlated with dose reduction and interruption, but not with efficacy. Conclusion: Cmin appears to correlate strongly with dasatinib toxicity but not with efficacy. The lowest Cmin was achieved with the 100 mg once-daily dose regimen, which has been shown to have the optimal therapeutic index among the regimens tested. Mean (CV%) ng/mL 100 mg QD 50 mg BID 140 mg QD 70 mg BID Cmin 2.69 (26) 5.13 (24) 3.86 (28) 6.9 (24) Cmax 66.85 (56) 37.6 (48) 94.09 (55) 53.71 (46) Cavg 14.16 (20) 14.32 (18) 19.96 (18) 20.34 (17) Cmin <2.5 Cmin 2.5-<5.0 Cmin >5.0 Pleural effusion (%) 4 14 25 Dose reduction (%) 26 45 59 Dose interruption (%) 51 64 75 Major cytogenetic response (%) 69 63 62 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb Bristol-Myers Squibb, Novartis Bristol-Myers Squibb, Innovive, Merck, Novartis, Wyeth
What problem does this paper attempt to address?